8BP Stock Overview
Biocorp Production designs, develops, and manufactures medical devices in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 8BP from our risk checks.
Biocorp Production Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €34.00 |
| 52 Week High | €35.00 |
| 52 Week Low | €13.65 |
| Beta | 0.96 |
| 11 Month Change | -2.30% |
| 3 Month Change | 0.29% |
| 1 Year Change | 149.08% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8BP | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 12.7% | 4.5% |
| 1Y | 149.1% | 9.1% | 13.4% |
Return vs Industry: 8BP exceeded the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: 8BP exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 8BP volatility | |
|---|---|
| 8BP Average Weekly Movement | 1.6% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8BP has not had significant price volatility in the past 3 months.
Volatility Over Time: 8BP's weekly volatility has decreased from 7% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 75 | Eric Dessertenne | biocorpsys.com |
Biocorp Production designs, develops, and manufactures medical devices in France. The company provides Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Datapen, a motor driven pen injector; and Injay which collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as NEWGUARD, a safety device compatible with various sizes of prefilled syringes; BIOPASS, a reconstitution system with a needle; Sween, a device that provides real assistance in the administration of medication and closure systems.
Biocorp Production Fundamentals Summary
| 8BP fundamental statistics | |
|---|---|
| Market cap | €154.53m |
| Earnings (TTM) | -€2.14m |
| Revenue (TTM) | €12.80m |
12.1x
P/S Ratio-72.3x
P/E RatioIs 8BP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8BP income statement (TTM) | |
|---|---|
| Revenue | €12.80m |
| Cost of Revenue | €5.24m |
| Gross Profit | €7.56m |
| Other Expenses | €9.70m |
| Earnings | -€2.14m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 59.05% |
| Net Profit Margin | -16.68% |
| Debt/Equity Ratio | 234.8% |
How did 8BP perform over the long term?
See historical performance and comparison